A biopharmaceutical company that pioneers antisense and RNA-targeting drug technology to develop treatments for cardiovascular, neurological and rare diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 61 | New buy | 13,000,000 | $14,282,450 | 0.0% |
| Steve Cohen / Point72 | 75 | Added +3571% | 1,255,588 | $56,062,004 | 0.1% |
| Paul Tudor Jones / Tudor | 61 | Added +20% | 47,382 | $2,115,606 | 0.0% |
| Ancora | 42 | Trimmed -10% | 2,000 | $89,300 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-07-31 | Hayden Michael R | director | 20,000 | $1,058,700 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.